<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048932</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-031</org_study_id>
    <nct_id>NCT00048932</nct_id>
  </id_info>
  <brief_title>A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if abatacept is safe when
      co-administered with other approved rheumatoid arthritis medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multinational, multicenter, randomized, double-blind, 2-arm, parallel-dosing
      designed study. The treatment period was 12 months. Eligible participants were randomized to
      1 of 2 treatment groups: abatacept fixed dose approximating 10 mg/kg (based on participant's
      body weight; 500 mg for participants weighing &lt; 60kg; 750 mg for participants weighing 60 to
      100 kg; and 1 gram for participants weighing &gt; 100 kg, monthly) or placebo intravenous (IV)
      infusion. All participants continued their background therapy(ies) for rheumatoid arthritis
      (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout
      the double-blind treatment period. Double-blind study medication (abatacept or placebo) was
      administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses.

      All participants who completed the 12-month double-blind study period (Day 1 through Day
      365), were eligible to continue into the open-label period. All eligible participants (active
      or placebo) were re-allocated to receive abatacept at a weight-tiered dose that approximated
      10 mg/kg, based on their Day 365 body weight. Participants continued to receive infusions
      every 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation</measure>
    <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DB; Number of Participants With AEs of Special Interest</measure>
    <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DB; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria</measure>
    <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DB; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality (MA) Criteria</measure>
    <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>ULN=upper level of normal; BL=baseline.Marked abnormality criteria: High alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; high aspartate aminotransferase (AST): &gt;3* ULN (80 U/L), or if BL&gt;ULN then use &gt;4* BL; high alanine aminotransferase (ALT): &gt;3* ULN (34-47 U/L), or if BL&gt;ULN then use &gt;4* BL; high G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; high bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; high blood urea nitrogen (BUN): &gt;2* BL; high creatinine: &gt;1.5* BL (ULN 14.6 pg/mg. AST ULN=80 U/L; ALT ULN=34-47 U/L;creatinine ULN=14.6 pg/mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DB; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities</measure>
    <time_frame>Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337. Vital signs were measured at these visits before and after study medication infusion.</time_frame>
    <description>Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Open Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation</measure>
    <time_frame>Day 365 to Day 1,821</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With AEs of Special Interest</measure>
    <time_frame>Day 365 to Day 1821</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria</measure>
    <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Liver Function Laboratories Meeting Marked Abnormality Criteria</measure>
    <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; aspartate aminotransferase (AST): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; alanine aminotransferase (ALT): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; Bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; blood urea nitrogen (BUN): &gt;2* BL; creatinine: &gt;1.5* BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Electrolyte Laboratories Meeting Marked Abnormality Criteria</measure>
    <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>Marked abnormality criteria: Sodium (Na): &lt;0.95*LLN/ &gt;1.05*ULN, or if BL&lt;LLN then use &lt;0.95* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1*ULN, or if BL&lt;LLN then use &lt;0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; (Cl): &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use &lt;0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use &lt;0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting Marked Abnormality Criteria</measure>
    <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
    <description>MA criteria: serum glucose (Glu): &lt;65 mg/dL/&gt;220 mg/dL;fasting serum Glu: &lt;0.8* LLN/&gt;1.5*ULN,or if BL&lt;LLN then use 0.8*BL or &gt;ULN,or if BL&gt;ULN then use &gt;2.0*BL or &lt;LLN;total protein: &lt;0.9*LLN/&gt;1.1*ULN,or if BL&lt;LLN then use &lt;0.9*BL or &gt;UNL,or if BL&gt;UNL then use &gt;1.1*BL or &lt;LLN; albumin: &lt;0.9*LLN,or if BL&lt;LLN then use &lt;0.75 BL;uric acid: &gt;1.5*ULN,or if BL&gt;ULN then use &gt;2*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities</measure>
    <time_frame>Days 365 to Day 1821</time_frame>
    <description>Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)</measure>
    <time_frame>Days 1, 29, 57, 85, 113,169, 281, 365</time_frame>
    <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA</measure>
    <time_frame>Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337</time_frame>
    <description>Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1795</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Double-blind abatacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label Abatacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double-blind Abatacept</intervention_name>
    <description>Concentrate and diluted in a solution, IV, 500 mg (body weight &lt; 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight &gt; 100 Kg), Once daily, Day 1, 15, and 29.</description>
    <arm_group_label>Double-blind abatacept</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>BMS-188667</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double-blind Placebo</intervention_name>
    <description>Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.</description>
    <arm_group_label>Double-blind Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open-label Abatacept</intervention_name>
    <description>Concentrate and diluted in a solution, IV, 500 mg (body weight &lt; 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight &gt; 100 Kg), Once daily, Every 28 days.</description>
    <arm_group_label>Open-label Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>BMS-188667</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet criteria of American Rheumatism Association for the diagnosis of rheumatoid
             arthritis and the American College of Rheumatology functional classes I, II III or IV

          -  Participants must be taking 1 or more DMARDs and/or biologic approved for rheumatoid
             arthritis (RA) for at least 3 months and be on a stable dose for 28 days prior to Day
             1.

        Exclusion:

          -  Other auto-immune disease as a main diagnosis (e.g. Systemic Lupus Erythematosus
             [SLE], Scleroderma)

          -  Active tuberculosis (TB) requiring treatment within last 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Decatur</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paradise</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Blairsville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Los Alamos</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ducktown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2002</study_first_submitted>
  <study_first_submitted_qc>November 12, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2002</study_first_posted>
  <results_first_submitted>April 1, 2011</results_first_submitted>
  <results_first_submitted_qc>April 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2011</results_first_posted>
  <last_update_submitted>November 15, 2011</last_update_submitted>
  <last_update_submitted_qc>November 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1795 enrolled in study and 339 were not randomized due to no longer meeting study criteria (n=214), withdraw of consent (n=83), other reasons (n=32), participant was lost to follow-up (n=5), administrative reason by sponsor (n=2), adverse event (n=2), and poor/non-compliance (n=1). Of 1456 randomized, 15 were not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abatacept (ABA)</title>
          <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (PLA)</title>
          <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Open Label (OL) Abatacept</title>
          <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Period (DB)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="959">Number Treated</participants>
                <participants group_id="P2" count="482">Number Treated</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="836"/>
                <participants group_id="P2" count="395"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative Reason By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uncontrolled hypertension</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 2 doses while undergoing work-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Period (OL)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1184">47 participants who completed the double-blind did not enter the open-label</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="743"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="441"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Retiring</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Transportation Issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Relocated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Dosing the Trial</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficult IV Access with Participant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Received Wrong Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Desires Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Missed Consecutive Doses</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication Lost Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Staff Issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Not Participating in Open Label</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abatacept (ABA)</title>
          <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (PLA)</title>
          <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="959"/>
            <count group_id="B2" value="482"/>
            <count group_id="B3" value="1441"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="11.7"/>
                    <measurement group_id="B2" value="52.1" spread="12.0"/>
                    <measurement group_id="B3" value="52.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="789"/>
                    <measurement group_id="B2" value="398"/>
                    <measurement group_id="B3" value="1187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug</description>
        <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Participants, all participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (ABA)</title>
            <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PLA)</title>
            <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug</description>
          <population>All Treated Participants, all participants who received at least 1 dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="866"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="534"/>
                    <measurement group_id="O2" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DB; Number of Participants With AEs of Special Interest</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
        <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Participants, all participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (ABA)</title>
            <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PLA)</title>
            <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With AEs of Special Interest</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
          <population>All Treated Participants, all participants who received at least 1 dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections/Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Infections/Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified Autoimmune Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified Acute Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified Peri-Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DB; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria</title>
        <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
        <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Population. One participant in each group was not evaluated for hematology abnormalities due to data unavailability (missing data).</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (ABA)</title>
            <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PLA)</title>
            <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria</title>
          <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
          <population>All Treated Population. One participant in each group was not evaluated for hematology abnormalities due to data unavailability (missing data).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="958"/>
                <count group_id="O2" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB (LLN=1.5%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit (LLN=36%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes (LLN=3.72-4.27 x10*6 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PLT (LLN=140-157*10^9 c/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT (ULN=415-440*10^9 c/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes (LLN= 4-9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes (ULN = 10.5-30*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands (LLN= 1.5-2.9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes (LLN= 0.7-2.9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High lymphocytes (ULN= 4.5-13.3*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes (ULN=1-3.9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High basophils (ULN= 0.6*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils (ULN= 1.5*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DB; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality (MA) Criteria</title>
        <description>ULN=upper level of normal; BL=baseline.Marked abnormality criteria: High alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; high aspartate aminotransferase (AST): &gt;3* ULN (80 U/L), or if BL&gt;ULN then use &gt;4* BL; high alanine aminotransferase (ALT): &gt;3* ULN (34-47 U/L), or if BL&gt;ULN then use &gt;4* BL; high G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; high bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; high blood urea nitrogen (BUN): &gt;2* BL; high creatinine: &gt;1.5* BL (ULN 14.6 pg/mg. AST ULN=80 U/L; ALT ULN=34-47 U/L;creatinine ULN=14.6 pg/mg.</description>
        <time_frame>Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Population. Two participants in the ABA group and 3 participants in the PLA group were not evaluated for blood chemistry abnormalities due to data unavailability (missing data).</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (ABA)</title>
            <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PLA)</title>
            <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality (MA) Criteria</title>
          <description>ULN=upper level of normal; BL=baseline.Marked abnormality criteria: High alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; high aspartate aminotransferase (AST): &gt;3* ULN (80 U/L), or if BL&gt;ULN then use &gt;4* BL; high alanine aminotransferase (ALT): &gt;3* ULN (34-47 U/L), or if BL&gt;ULN then use &gt;4* BL; high G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; high bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; high blood urea nitrogen (BUN): &gt;2* BL; high creatinine: &gt;1.5* BL (ULN 14.6 pg/mg. AST ULN=80 U/L; ALT ULN=34-47 U/L;creatinine ULN=14.6 pg/mg.</description>
          <population>All Treated Population. Two participants in the ABA group and 3 participants in the PLA group were not evaluated for blood chemistry abnormalities due to data unavailability (missing data).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="957"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High AST (ULN=80 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (ULN=34-47 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine (ULN=14.6 pg/mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)</title>
        <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
        <time_frame>Days 1, 29, 57, 85, 113,169, 281, 365</time_frame>
        <population>All participants treated during DB who received at least 1 dose of abatacept and had antibody samples collected at baseline and at least 1 post-baseline visit. 561 participants were not evaluated for anti-abatacept anti-bodies during the DB.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated Participants</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)</title>
          <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
          <population>All participants treated during DB who received at least 1 dose of abatacept and had antibody samples collected at baseline and at least 1 post-baseline visit. 561 participants were not evaluated for anti-abatacept anti-bodies during the DB.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="880"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-abatacept antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CTLA4 antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DB; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities</title>
        <description>Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.</description>
        <time_frame>Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337. Vital signs were measured at these visits before and after study medication infusion.</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (ABA)</title>
            <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PLA)</title>
            <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities</title>
          <description>Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.</description>
          <population>All Treated Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Open Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug</description>
        <time_frame>Day 365 to Day 1,821</time_frame>
        <population>All Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>OL ABA</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>Open Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug</description>
          <population>All Treated Participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With AEs of Special Interest</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
        <time_frame>Day 365 to Day 1821</time_frame>
        <population>All Treated Participants, all participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>OL ABA</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With AEs of Special Interest</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
          <population>All Treated Participants, all participants who received at least 1 dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections/Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant Neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benign and Unspecified Neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified Autoimmune Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified Acute Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified Peri-Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria</title>
        <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
        <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>OL ABA</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria</title>
          <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
          <population>All Treated Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB (LLN=1.5%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit (LLN=36%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes (LLN=3.72-4.27 x10*6 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PLT (LLN=140-157*10^9 c/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT (ULN=415-440*10^9 c/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes (LLN= 4-9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes (ULN = 10.5-30*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands (LLN= 1.5-2.9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes (LLN= 0.7-2.9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High lymphocytes (ULN= 4.5-13.3*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes (ULN=1-3.9*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High basophils (ULN= 0.6*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils (ULN= 1.5*10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Liver Function Laboratories Meeting Marked Abnormality Criteria</title>
        <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; aspartate aminotransferase (AST): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; alanine aminotransferase (ALT): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; Bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; blood urea nitrogen (BUN): &gt;2* BL; creatinine: &gt;1.5* BL</description>
        <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Population. One participant was not evaluated for liver function abnormalities.</population>
        <group_list>
          <group group_id="O1">
            <title>OL ABA</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Liver Function Laboratories Meeting Marked Abnormality Criteria</title>
          <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; aspartate aminotransferase (AST): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; alanine aminotransferase (ALT): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; Bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; blood urea nitrogen (BUN): &gt;2* BL; creatinine: &gt;1.5* BL</description>
          <population>All Treated Population. One participant was not evaluated for liver function abnormalities.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALP (ULN=150 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (ULN=80 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (ULN=34-47 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT (ULN=43-54 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High bilirubin (ULN=0.3 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN (normal=4-25 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine (ULN=14.6 pg/mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Electrolyte Laboratories Meeting Marked Abnormality Criteria</title>
        <description>Marked abnormality criteria: Sodium (Na): &lt;0.95*LLN/ &gt;1.05*ULN, or if BL&lt;LLN then use &lt;0.95* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1*ULN, or if BL&lt;LLN then use &lt;0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; (Cl): &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use &lt;0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use &lt;0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
        <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Population. One participant was not evaluated for electrolyte abnormalities.</population>
        <group_list>
          <group group_id="O1">
            <title>OL ABA</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Electrolyte Laboratories Meeting Marked Abnormality Criteria</title>
          <description>Marked abnormality criteria: Sodium (Na): &lt;0.95*LLN/ &gt;1.05*ULN, or if BL&lt;LLN then use &lt;0.95* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1*ULN, or if BL&lt;LLN then use &lt;0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; (Cl): &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use &lt;0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use &lt;0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
          <population>All Treated Population. One participant was not evaluated for electrolyte abnormalities.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Na (LLN=135 mEq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Na (ULN=148 mEq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low K (LLN=3.5 mEq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High K (ULN=5.5 mEq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Cl (LLN= 96 mEq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Cl (ULN=109 mEq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca (LLN=8.5 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca (ULN=11 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low P (LLN=2.5 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High P (ULN 7.1 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting Marked Abnormality Criteria</title>
        <description>MA criteria: serum glucose (Glu): &lt;65 mg/dL/&gt;220 mg/dL;fasting serum Glu: &lt;0.8* LLN/&gt;1.5*ULN,or if BL&lt;LLN then use 0.8*BL or &gt;ULN,or if BL&gt;ULN then use &gt;2.0*BL or &lt;LLN;total protein: &lt;0.9*LLN/&gt;1.1*ULN,or if BL&lt;LLN then use &lt;0.9*BL or &gt;UNL,or if BL&gt;UNL then use &gt;1.1*BL or &lt;LLN; albumin: &lt;0.9*LLN,or if BL&lt;LLN then use &lt;0.75 BL;uric acid: &gt;1.5*ULN,or if BL&gt;ULN then use &gt;2*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3</description>
        <time_frame>Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication</time_frame>
        <population>All Treated Population. N=Number of Participants Analyzed, n=number of participants with measurements at time point</population>
        <group_list>
          <group group_id="O1">
            <title>OL ABA</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting Marked Abnormality Criteria</title>
          <description>MA criteria: serum glucose (Glu): &lt;65 mg/dL/&gt;220 mg/dL;fasting serum Glu: &lt;0.8* LLN/&gt;1.5*ULN,or if BL&lt;LLN then use 0.8*BL or &gt;ULN,or if BL&gt;ULN then use &gt;2.0*BL or &lt;LLN;total protein: &lt;0.9*LLN/&gt;1.1*ULN,or if BL&lt;LLN then use &lt;0.9*BL or &gt;UNL,or if BL&gt;UNL then use &gt;1.1*BL or &lt;LLN; albumin: &lt;0.9*LLN,or if BL&lt;LLN then use &lt;0.75 BL;uric acid: &gt;1.5*ULN,or if BL&gt;ULN then use &gt;2*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3</description>
          <population>All Treated Population. N=Number of Participants Analyzed, n=number of participants with measurements at time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Glu, n=1184</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu, n=1184</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low fasting Glu, n=647 (LLN=65 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High fasting Glu, n=647 (ULN=115 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein, n=1183 (LLN=6 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High protein, n=1183 (ULN=8.5 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin, n=1183 (LLN=3.5 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High uric acid, n=1183 (ULN=8.7 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein, n=1184 (normal=trace)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine glucose, n=1184 (normal=negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine ketones, n=33 (normal=negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood, n=1184 (normal=negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocyte esterase, n=32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC, n=852</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC, n=852</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities</title>
        <description>Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.</description>
        <time_frame>Days 365 to Day 1821</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>OL ABA</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities</title>
          <description>Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.</description>
          <population>All Treated Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA</title>
        <description>Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
        <time_frame>Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337</time_frame>
        <population>All DB participants treated on study who received at least 1 dose of abatacept and had antibody samples collected at baseline and at least 1 post-baseline visit. 68 participants were not evaluated for anti-abatacept anti-bodies on study.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated Participants</title>
            <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA</title>
          <description>Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
          <population>All DB participants treated on study who received at least 1 dose of abatacept and had antibody samples collected at baseline and at least 1 post-baseline visit. 68 participants were not evaluated for anti-abatacept anti-bodies on study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-abatacept antibodies (n=1228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CTLA4 antibodies (n=1296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total antibodies (n=1296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open Label (OL) Abatacept</title>
          <description>Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.</description>
        </group>
        <group group_id="E2">
          <title>Abatacept (ABA)</title>
          <description>Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for subjects &lt; 60 kg, 750 mg for subjects 60 to 100 kg and 1 g for subjects &gt; 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (PLA)</title>
          <description>Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="425" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BONE MARROW FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BONE MARROW TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HEART VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE HEART DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>CONGENITAL CEREBRAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEAFNESS NEUROSENSORY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NEUROSENSORY HYPOACUSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PTERYGIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SCLEROMALACIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GINGIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>COLONIC ATONY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MESENTERIC ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HEPATIC MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CERVICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HEPATITIS E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BONE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ASPERGILLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SYSTEMIC MYCOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BONE TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CANDIDA PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHRONIC SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HUMAN EHRLICHIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIARRHOEA INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PERITONSILLAR ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PNEUMONIA HAEMOPHILUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RESPIRATORY MONILIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LYMPH NODE TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INCISION SITE CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CELLULITIS STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SALMONELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PELVIC INFLAMMATORY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY ASPERGILLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECI PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UNDERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>STRESS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MEDICATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BURNS THIRD DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PUBIC RAMI FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LIMB CRUSHING INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>TRAUMATIC LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF VERTEBRA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DRUG ADMINISTRATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>THERAPEUTIC AGENT TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INCORRECT DOSE ADMINISTERED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SUTURE RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF JOINT PROSTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HIV TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HAEMATOCRIT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST-T SEGMENT ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BONE EROSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HAND DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>JOINT ANKYLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FINGER DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>JOINT DESTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RHEUMATOID NODULE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OSTEOPOROTIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OSTEOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ADENOMA BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LEIOMYOSARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>KAPOSI'S SARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SEBACEOUS CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BREAST CANCER IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA STAGE II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE CERVIX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MOYAMOYA DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SPINAL CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NERVE ROOT COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RUPTURED CEREBRAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>COMPLEX REGIONAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL INFARCT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RENAL AMYLOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>STRESS URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ADENOMYOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GYNAECOMASTIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CERVICAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BREAST DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MENOMETRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>FIBROCYSTIC BREAST DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHIAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RHEUMATOID LUNG</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>TRACHEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>STATUS ASTHMATICUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PANNICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>LICHENOID KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PYODERMA GANGRENOSUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DERMATITIS PSORIASIFORM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>VICTIM OF HOMICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>EXTREMITY NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>VASCULAR OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RHEUMATOID VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>AXILLARY VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1010" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="715" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="346" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="362" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="195" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="1184"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="959"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

